Johnson & Johnson (JNJ)vsLive Nation Entertainment Inc (LYV)
JNJ
Johnson & Johnson
$221.32
-0.53%
HEALTHCARE · Cap: $535.63B
LYV
Live Nation Entertainment Inc
$163.28
-1.49%
COMMUNICATION SERVICES · Cap: $38.57B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 276% more annual revenue ($96.36B vs $25.61B). JNJ leads profitability with a 21.8% profit margin vs 0.3%. JNJ appears more attractively valued with a PEG of 2.92. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LYV
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.5%
Fair Value
$160.72
Current Price
$221.32
$60.60 premium
Margin of Safety
+12.2%
Fair Value
$172.04
Current Price
$163.28
$8.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Generating 2.0B in free cash flow
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.3% margin — thin
Weak financial health signals
Expensive relative to growth rate
Trading at 140.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : LYV
The strongest argument for LYV centers on Free Cash Flow. Revenue growth of 12.2% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : LYV
The primary concerns for LYV are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 0.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LYV is a value play — different risk/reward profiles.
LYV carries more volatility with a beta of 1.11 — expect wider price swings.
LYV is growing revenue faster at 12.2% — sustainability is the question.
LYV generates stronger free cash flow (2.0B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 42/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Live Nation Entertainment Inc
COMMUNICATION SERVICES · ENTERTAINMENT · USA
Live Nation Entertainment, Inc is an American global entertainment company, founded in 2010, following the merger of Live Nation and Ticketmaster. The company promotes, operates, and manages ticket sales for live entertainment in the United States and internationally. It also owns and operates entertainment venues, and manages the careers of music artists.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?